FASN and neoplasm: Blocking FASN activity causes in vitro and in vivo anticancer activity by inhibiting tumor progression [23,24,25,26,27,28], hindering angiogenesis [29,30], overcoming drug-resistance [31,32], and synergistically increasing the efficacy of chemotherapy [26,33,34].